Information Provided By:
Fly News Breaks for December 28, 2015
CMRX
Dec 28, 2015 | 13:39 EDT
Cowen analyst Phil Nadeau downgraded Chimerix to Market Perform with a reduced price target of $8 after brinicidofovir's SUPPRESS trial missed its endpoint. Three other analysts downgraded the stock today.
News For CMRX From the Last 2 Days
There are no results for your query CMRX